ImmunoForge Plans Strategic Partnerships at Bio-Europe Spring 2026 in Portugal
ImmunoForge to Engage in Strategic Partnering at Bio-Europe Spring 2026
ImmunoForge Co., Ltd., a prominent biopharmaceutical firm focused on rare disease treatments, has announced its participation in the upcoming Bio-Europe Spring 2026, scheduled from March 23rd to 25th in Lisbon, Portugal. During this significant event, the company aims to foster strategic collaborations with global pharmaceutical firms and investors.
Instead of making an official presentation on stage, ImmunoForge plans to hold focused meetings with representatives from overseas pharmaceutical companies. These discussions will center around clinical advancements and the global transfer of technology related to their lead development assets: PF1801, currently in Phase 2 trials, and PF1804, which has also gained Phase 2 approval.
Focus on Innovative Technology
One of the key highlights of ImmunoForge's strategy is the introduction of its LMT15 Platform. This innovative platform allows for both blood-brain barrier (BBB) penetration and prolonged drug delivery, making it a groundbreaking solution in the biopharmaceutical industry. The LMT15 technology incorporates Elastin-Like Polypeptide (ELP) with a unique peptide that utilizes Leptin receptor-mediated transcytosis, showcasing a dual capability for effectively targeting the central nervous system (CNS).
Long-Acting ELP Platform
The company also aims to discuss their ELP Platform, which supports long-acting drug administration solutions, helping to extend the lifetimes of peptide-based medications. This technology potentially allows for dosing intervals ranging from weekly to monthly, addressing a critical need in treatment compliance for patients with chronic conditions.
Promising Clinical Candidates
- - PF1801: Currently in Phase 2 clinical trials targeting Polymyositis and Dermatomyositis in South Korea. The U.S. FDA has granted Phase 2 IND clearance, setting the stage for immediate clinical launches in the U.S. through global partnerships.
- - PF1804: Targeting cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), this candidate has also secured FDA clearance for Phase 2 studies and is ready for clinical execution with the right partners.
Kiho Chang, co-CEO of ImmunoForge, expressed enthusiasm for the upcoming Bio-Europe Spring 2026.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.